Harpoon Therapeutics (Harpoon Therapeutics) Revenue per Share : $9.99 (TTM As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Harpoon Therapeutics Revenue per Share?

Harpoon Therapeutics's revenue per share for the three months ended in Sep. 2023 was $1.13. Harpoon Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Sep. 2023 was $9.99.

Warning Sign:

Harpoon Therapeutics Inc revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue Per Share Growth Rate of Harpoon Therapeutics was 2.40% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 53.60% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 65.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Harpoon Therapeutics's Revenue per Share or its related term are showing as below:

HARP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 53.6 Med: 54.5 Max: 110.3
Current: 53.6

During the past 7 years, Harpoon Therapeutics's highest 3-Year average Revenue Per Share Growth Rate was 110.30% per year. The lowest was 53.60% per year. And the median was 54.50% per year.

HARP's 3-Year Revenue Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 5.5 vs HARP: 53.60

Harpoon Therapeutics Revenue per Share Historical Data

The historical data trend for Harpoon Therapeutics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harpoon Therapeutics Revenue per Share Chart

Harpoon Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Revenue per Share

Get a 7-Day Free Trial

1.99

2.66

6.97

7.33

9.62

Harpoon Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Revenue per Share	Get a 7-Day Free Trial															4.12	1.21	2.32	5.33	1.13

Competitive Comparison of Harpoon Therapeutics's Revenue per Share

For the Biotechnology subindustry, Harpoon Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harpoon Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harpoon Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Harpoon Therapeutics's PS Ratio falls into.

Harpoon Therapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Harpoon Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2022 is calculated as

Revenue Per Share (A: Dec. 2022 )	=	Revenue (A: Dec. 2022 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2022 )
	=	31.915	/	3.317
	=	9.62

Harpoon Therapeutics's Revenue Per Share for the quarter that ended in Sep. 2023 is calculated as

Revenue Per Share (Q: Sep. 2023 )	=	Revenue (Q: Sep. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Sep. 2023 )
	=	4.448	/	3.948
	=	1.13

Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.99

Harpoon Therapeutics (NAS:HARP) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Harpoon Therapeutics Revenue per Share Related Terms

Thank you for viewing the detailed overview of Harpoon Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Harpoon Therapeutics (Harpoon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harpoon Therapeutics Inc (NAS:HARP) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

5HTA:Germany

Address

131 Oyster Point Boulevard, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.harpoontx.com

Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.

Executives

Vijay K Lathi	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 2500 SAND HILL ROAD, SUITE 203, MENLO PARK CA 94025
Luke Nathaniel Walker	officer: Chief Medical Officer	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Frank J Lanza	officer: Principal Fin. & Acctng Ofc.	C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Lauren P Silvernail	director	15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Georgia Erbez	officer: Chief Financial Officer	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Oncology Impact Fund (cayman) Management L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p.	10 percent owner	C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Alan Colowick	director	C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063
New Leaf Bpo Associates Ii, L.p.	10 percent owner	420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
Ronald Hunt	director, 10 percent owner	C/O CREDIT SUISSE 1ST BOSTON PRV EQY, 11 MADISON AVENUE, NEW YORK NY 10010
New Leaf Bpo Management Ii, L.l.c	10 percent owner	420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
New Leaf Ventures Iii, L.p.	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Associates Iii, L.p.	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Management Iii, L.l.c.	10 percent owner	C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Biopharma Opportunities Ii, L.p.	10 percent owner	420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170